Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

01-12-2020 | Stroke | Original investigation

Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II

Authors: Jocelyn J. Drinkwater, Timothy M. E. Davis, Valentina Hellbusch, Angus W. Turner, David G. Bruce, Wendy A. Davis

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Background

Microangiopathy in type 2 diabetes (T2D) is associated with cardiovascular disease (CVD), but most relevant studies were performed > 10 years ago. CVD risk factor management has since improved. The aim of this study was to determine whether diabetic retinopathy (DR) and its severity increases stroke and myocardial infarction (MI) risk in a contemporary cohort.

Methods

Fremantle Diabetes Study Phase II participants with T2D had DR graded from fundus photography at baseline between 2008 and 2011. Subsequent hospitalizations and mortality for MI or stroke were ascertained through validated data linkage to end-2016. Cox regression modelling identified predictors of first stroke and MI including DR presence and severity.

Results

The 1521 participants with T2D and known DR status (mean age 65.6 years, 52.1% males, median diabetes duration 9.0 years) were followed for a mean of 6.6 years. After excluding those with prior MI/stroke, there were 126 incident MIs among 1393 eligible participants and 53 incident strokes in 1473 eligible participants, respectively. Moderate non-proliferative DR (NPDR) or worse was significantly and independently associated with an increased risk of incident stroke (adjusted hazard ratio 2.55 (95% CI 1.19, 5.47), p = 0.016). Retinopathy presence and severity increased the risk of incident MI in unadjusted models (p ≤ 0.001), but these associations were no longer statistically significant after adjusting for other risk factors.

Conclusions

Moderate NPDR or worse was associated with an increased risk of first stroke in Australians with T2D. Intensified CVD risk factor management should be considered for patients with at least moderate NPDR.
Appendix
Available only for authorised users
Literature
6.
go back to reference Kim Y-H, Hong M-K, Lee CW, Song J-M, Han K-H, Kang D-H, et al. Diabetic retinopathy as a predictor of late clinical events following percutaneous coronary intervention. J Invasive Cardiol. 2002;14(10):599–602.PubMed Kim Y-H, Hong M-K, Lee CW, Song J-M, Han K-H, Kang D-H, et al. Diabetic retinopathy as a predictor of late clinical events following percutaneous coronary intervention. J Invasive Cardiol. 2002;14(10):599–602.PubMed
28.
go back to reference Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.CrossRef Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019;41(2):255–323. https://​doi.​org/​10.​1093/​eurheartj/​ehz486.CrossRef
29.
go back to reference O’Sullivan JJ, Conroy RM, MacDonald K, McKenna TJ, Maurer BJ. Silent ischaemia in diabetic men with autonomic neuropathy. Brit Heart J. 1991;66(4):313–5.CrossRefPubMedPubMedCentral O’Sullivan JJ, Conroy RM, MacDonald K, McKenna TJ, Maurer BJ. Silent ischaemia in diabetic men with autonomic neuropathy. Brit Heart J. 1991;66(4):313–5.CrossRefPubMedPubMedCentral
30.
go back to reference Garofolo M, Gualdani E, Giannarelli R, Aragona M, Campi F, Lucchesi D, et al. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. Cardiovasc Diabetol. 2019;18(159):1–16. https://doi.org/10.1186/s12933-019-0961-7.CrossRef Garofolo M, Gualdani E, Giannarelli R, Aragona M, Campi F, Lucchesi D, et al. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. Cardiovasc Diabetol. 2019;18(159):1–16. https://​doi.​org/​10.​1186/​s12933-019-0961-7.CrossRef
38.
go back to reference Cardoso CRL, Salles GC, Leite NC, Salles GF. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2019;18(2):1–13. https://doi.org/10.1186/s12933-019-0809-1.CrossRef Cardoso CRL, Salles GC, Leite NC, Salles GF. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2019;18(2):1–13. https://​doi.​org/​10.​1186/​s12933-019-0809-1.CrossRef
41.
go back to reference Cheung N, Liew G, Wong TY. Current approaches to retinopathy as a predictor of cardiovascular risk. In: Hammes H-P, Porta M, editors. Experimental approaches to diabetic retinopathy. Basel: Karger; 2009. p. 203–19.CrossRef Cheung N, Liew G, Wong TY. Current approaches to retinopathy as a predictor of cardiovascular risk. In: Hammes H-P, Porta M, editors. Experimental approaches to diabetic retinopathy. Basel: Karger; 2009. p. 203–19.CrossRef
Metadata
Title
Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II
Authors
Jocelyn J. Drinkwater
Timothy M. E. Davis
Valentina Hellbusch
Angus W. Turner
David G. Bruce
Wendy A. Davis
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-020-01018-3

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.